Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

Results 11-20 of 36
Item hits:
Issue DateTitleAuthor(s)
17-Nov-2020Repurposing fostamatinib to combat SARS-CoV-2-induced acute lung injury.Tabassum, N; Zhang, H; Stebbing, J;
2-May-2020CNS penetration of potential anti-COVID-19 drugs.Richardson, PJ; Ottaviani, S; Prelle, A; Stebbing, J; Casalini, G, et al
20-Jun-2021Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trialStebbing, J; Baranau, Y; Baryash, V; Manikhas, A; Moiseyenko, V, et al
7-Jun-2021Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patientsNteliopoulos, G; Page, K; Hills, A; Howarth, K; Emmett, W, et al
-Immunotherapy-related cystitis: case report and review of the literatureZhu, L; Wang, Z; Stebbing, J; Wang, Z; Peng, L, et al
Nov-2020Sports balls as potential SARS-CoV-2 transmission vectors.Pelisser, M; Thompson, J; Majra, D; Youhanna, S; Stebbing, J, et al
23-Jun-2021First-line treatment options for PD-L1-negative non-small cell lung cancer: a Bayesian network meta-analysisPeng, L; Liang, W-H; Mu, D-G; Xu, S; Hong, S-D, et al
31-Jul-2020A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.Peng, L; Xiao, K; Ottaviani, S; Stebbing, J; Wang, Y-J, et al
15-Apr-2020Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patientsStebbing, J; Krishnan, V; Bono, SD; Ottaviani, S; Casalini, G, et al
1-Jul-2017CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trialStebbing, J; Baranau, Y; Baryash, V; Manikhas, A; Moiseyenko, V, et al